Pharming Group to convene Extraordinary General Meeting of Shareholders
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) has announced an Extraordinary General Meeting (EGM) scheduled for March 4, 2025, at 14:00 CET. The primary purpose is to appoint Fabrice Chouraqui as Executive Director and Chief Executive Officer for a four-year term, succeeding Sijmen de Vries. The agenda includes approving components of Chouraqui's remuneration package.
The meeting will be held physically at the Corpus Congress Centre in Oegstgeest, Netherlands, with shareholders having the option to attend in person or follow via live webcast. All relevant documents, including the Notice to Convene, Explanatory Notes, and voting information, are available on the company's website under the Investors/Shareholder Meetings section.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) ha annunciato una Assemblea Generale Straordinaria (EGM) programmata per il 4 marzo 2025, alle 14:00 CET. L'obiettivo principale è nominare Fabrice Chouraqui come Direttore Esecutivo e Amministratore Delegato per un mandato di quattro anni, succedendo a Sijmen de Vries. L'ordine del giorno include l'approvazione dei componenti del pacchetto retributivo di Chouraqui.
L'incontro si terrà fisicamente presso il Corpus Congress Centre di Oegstgeest, Paesi Bassi, con gli azionisti che hanno la possibilità di partecipare di persona o di seguire tramite webcast dal vivo. Tutti i documenti relevanti, inclusi l'Avviso di Convocazione, le Note Esplicative e le informazioni di voto, sono disponibili sul sito web dell'azienda nella sezione Investitori/Assemblee degli Azionisti.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) ha anunciado una Asamblea General Extraordinaria (EGM) programada para el 4 de marzo de 2025, a las 14:00 CET. El propósito principal es nombrar a Fabrice Chouraqui como Director Ejecutivo y Consejero Delegado por un periodo de cuatro años, sucediendo a Sijmen de Vries. La agenda incluye la aprobación de los componentes del paquete de remuneración de Chouraqui.
La reunión se llevará a cabo de manera física en el Corpus Congress Centre en Oegstgeest, Países Bajos, con los accionistas teniendo la opción de asistir en persona o seguir la transmisión en vivo. Todos los documentos relevantes, incluido el Aviso de Convocatoria, las Notas Explicativas y la información sobre votación, están disponibles en el sitio web de la empresa en la sección de Inversores/Reuniones de Accionistas.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR)는 2025년 3월 4일 오후 2시 CET에 임시 주주총회 (EGM)를 개최할 예정이라고 발표했습니다. 주요 목적은 Fabrice Chouraqui를 4년 임기로 임원 및 최고 경영자로 임명하는 것이며, Sijmen de Vries를 대신하게 됩니다. 의제에는 Chouraqui의 보수 패키지 구성 요소 승인도 포함되어 있습니다.
회의는 네덜란드 오에흐스트헤이스에 있는 Corpus Congress Centre에서 대면으로 진행되며, 주주들은 직접 참석하거나 실시간 웹캐스트를 통해 참석할 수 있는 선택권이 있습니다. 관련 문서들, 즉 소집 통지서, 설명서 및 투표 정보는 회사 웹사이트의 투자자/주주 회의 섹션에서 확인할 수 있습니다.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) a annoncé une Assemblée Générale Extraordinaire (EGM) prévue pour le 4 mars 2025 à 14h00 CET. Le principal objectif est de nommer Fabrice Chouraqui en tant que Directeur Exécutif et Directeur Général pour un mandat de quatre ans, succédant à Sijmen de Vries. L'ordre du jour inclut l'approbation des éléments du package de rémunération de Chouraqui.
La réunion se tiendra physiquement au Corpus Congress Centre à Oegstgeest, aux Pays-Bas, avec la possibilité pour les actionnaires de participer en personne ou de suivre via un webinaire en direct. Tous les documents pertinents, y compris l'Avis de Convocation, les Notes Explicatives et les informations de vote, sont disponibles sur le site web de la société dans la section Investisseurs/Assemblées Générales.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) hat eine außerordentliche Hauptversammlung (EGM) für den 4. März 2025 um 14:00 CET angekündigt. Der Hauptzweck besteht darin, Fabrice Chouraqui für eine vierjährige Amtszeit als Geschäftsführender Direktor und Chief Executive Officer zu ernennen, um Sijmen de Vries nachzufolgen. Die Tagesordnung umfasst die Genehmigung der Bestandteile von Chouraquis Vergütungspaket.
Die Versammlung findet physisch im Corpus Congress Centre in Oegstgeest, Niederlande, statt, wobei den Aktionären die Möglichkeit gegeben wird, persönlich teilzunehmen oder die Veranstaltung über einen Live-Webcast zu verfolgen. Alle relevanten Dokumente, einschließlich der Einladung, erläuternde Notizen und Informationen zur Abstimmung, sind auf der Website des Unternehmens im Bereich Investoren/Hauptversammlungen verfügbar.
- None.
- None.
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on March 4, 2025, at 14:00 CET. The Notice to Convene, Explanatory Notes, Voting information, meeting documents and Form of Proxy can be found on the Company’s website under Investors/Shareholder Meetings.
The EGM is convened for the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years, based on a binding nomination by the Board of Directors. Mr. Chouraqui will be successor to Mr. Sijmen de Vries, subject to (and therefore effective as of) his appointment as Executive Director and Chief Executive Officer at the EGM.
The agenda further includes the proposal to approve certain components of the remuneration package of Mr. Chouraqui in his capacity as Executive Director and Chief Executive Officer. Details can be found in the Explanatory Notes for the EGM and the summary of the remuneration package as available on the Company’s website under Investors/Shareholder Meetings.
The EGM will be held as a physical meeting at the Corpus Congress Centre, Willem Einthovenstraat 1, 2342 BH in Oegstgeest, the Netherlands. Our shareholders are invited to attend the EGM in person or to follow the meeting through our live webcast.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
When is Pharming Group's (PHARM) Extraordinary General Meeting in 2025?
Who is being appointed as the new CEO of Pharming Group (PHARM)?
Where can shareholders find the EGM documents for Pharming Group (PHARM)?
How can shareholders participate in Pharming Group's (PHARM) March 2025 EGM?
